ĐÁNH GIÁ MỘT SỐ TÁC DỤNG KHÔNG MONG MUỐN TRÊN BỆNH NHÂN SARCÔM THÂN TỬ CUNG ĐIỀU TRỊ BẰNG PHÁC ĐỒ DOCETAXEL GEMCITABIN TẠI BỆNH VIỆN K

Abstract

Objectives: Evaluate side effects of docetaxel gemcitabine regimen in patients with uterine sarcomas. Materials and methods: This descriptive study used medical record of patients diagnosed uterine sarcomas who received docetaxel gemcitabine regimen at National Cancer Hospital from January 2016 to November 2023. Results: A total of 31 patients with uterine sarcomas were included in this study. Common side effects on the hematopoietic system: neutropenia grade 1-2 is 25.8%, grade 3 is 6.5%, grade 4 neutropenia was 12.9%. Rate of grade 1 decreased hemoglobin was 41.9%; grade 2 decreased hemoglobin for 18.3%. There were 5 cases of grade 3 hemoglobin reduction for 16.1%. There was 1 case of a patient with grade 4 decreased hemoglobin for 3.2%. The rate of thrombocytopenia grade 1 is 35.5%, grade 2 is 14.1%, grade 3 is 16.1%, grade 4 is 6.5%. Side effects on the liver occurred at a rate of 25.9%, of which only grade 1 and 2 toxicity, with no cases of grade 3 or 4. Increased creatinine occurred in 9.7% of patients. Other side effects included nausea/vomiting in 32.2% of patients. Fatigue occurred in 87.1%, sensory neuropathy in 38.8% of patients, diarrhea in 35.5%, hair loss in 83.9%, muscle and joint pain in 45.2%, and drug allergy in 9.7%. Conclusions: Docetaxel gemcitabine regimen is well tolerated. Severe side effects are rare.